title: [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
abstract: OBJECTIVE
  an attempt to determine the value of the simultaneous quantization of osteopontin (OPN), insulin-growth factor II (IGF II), leptin, prolactin and CA 125 for early detection of ovarian cancer.
  
  
  METHODS
  Prospective study of 69 women including: 15 females with ovarian cancer; 33 females with benign ovarian neoplasm; 21 disease-free females; The levels of IGF II, prolactin, leptin and CA 125 were determined in serum, while the level of OPN was checked in plasma.
  
  
  RESULTS
  The concentrations of IGF II, leptin and prolactin do not let us distinguish among disease-free females, females with ovarian cancer and those with benign ovarian neoplasms on the basis of biochemical markers. The comparison of OPN and CA 125 levels showed significant differences in the concentrations of the biomarkers between disease-free females and females with ovarian cancer, as well as between females with benign ovarian neoplasms and females with ovarian cancer. The ROC curves for two groups: disease-free females and females with ovarian cancer, proved the diagnostic value of OPN and CA 125.
  
  
  CONCLUSIONS
  The simultaneous quantization of OPN, IGF II leptin and prolactin has not been proved useful for the early detection of ovarian cancer. Statistically significant increase of OPN & CA 125 levels was noted in case of women with ovarian cancer diagnosed through microscopic examination. The analysis of ROC curves showed comparable diagnostic usefulness of both markers. Quantization of OPN may have an additional value for treatment monitoring of women diagnosed with ovarian cancer but with concentration of CA 125 within the reference value.
authors.affiliation: Zakład Analityki i Biochemii Klinicznej, Centrum Onkologii Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach, Gliwice. jmrochem@io.gliwice.pl
authors.forename: Jolanta
authors.initials: J
authors.lastname: Mrochem
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Sodowski
authors.forename: Regina
authors.initials: R
authors.lastname: Deja
authors.forename: Aneta
authors.initials: A
authors.lastname: Walaszek-Gruszka
authors.forename: Andrzej
authors.initials: A
authors.lastname: Wojcieszek
authors.forename: Zofia
authors.initials: Z
authors.lastname: Kołosza
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Chmura
authors.forename: Ewa
authors.initials: E
authors.lastname: Czernik
authors.forename: Barbara
authors.initials: B
authors.lastname: Masłyk
authors.forename: Wiesława
authors.initials: W
authors.lastname: Bartnik
authors.forename: Wojciech
authors.initials: W
authors.lastname: Cnota
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000032:analysis; D020738:Leptin / Q000097:blood; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis*; D011044:Poland; D011388:Prolactin / Q000097:blood; D011446:Prospective Studies; D012372:ROC Curve; D012016:Reference Values; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C035170:IGF2 protein, human; D020738:Leptin; D053495:Osteopontin; D007335:Insulin-Like Growth Factor II; D011388:Prolactin